Get it now! Latest usage guidelines for lorlatinib in 2024

Lorlatinib is a new generation tyrosine kinase inhibitor that is widely used to treat ALK (tyrosine kinase) or ROS proto-oncogene in non-small cell lung cancer (NSCLC) 1) Gene mutation. To ensure patients receive the full benefit and to minimize potential side effects, the following are guidelines for the use of lorlatinib.

1. Patient selection and genetic testing: Lorlatinib is mainly suitable for ALK or ROS1 positive NSCLC patients. Therefore, genetic testing should be performed to confirm whether the patient has these gene mutations before starting treatment. Doctors will consider whether to include lorlatinib in the treatment plan based on the test results, the patient's medical history and overall health.

2. Dosage and dosage: Lorlatinib is usually an oral medication that can be taken with food or on an empty stomach. Patients should take it on time according to the doctor's advice and avoid missing doses or overdosing. Determination of initial dosage is usually based on the individual patient's condition, general health, and possible interactions. Dose adjustments may be made based on patient response.

3. Regular monitoring and examination: During the treatment process, doctors will conduct regular physical examinations, blood tests and imaging examinations to evaluate the patient's condition and the effectiveness of the drugs. Of particular note is the effect of lorlatinib on liver function, so patients may need to undergo regular liver function tests.

4. Handling side effects and adverse reactions: Lorlatinib may cause a series of adverse reactions, including but not limited to visual impairment, abnormal liver function, gastrointestinal discomfort, etc. Patients should pay close attention to these reactions while taking the medication. If any discomfort or unusual symptoms occur, patients should report to their doctor promptly so that the treatment plan can be adjusted or appropriate intervention measures can be taken.

5. Therapeutic strategy for brain metastases: Lorlatinib has the ability to cross the blood-brain barrier, so it is useful in the treatment of brain metastasesNSCLCshowed good results in patients. Lorlatinib may be an effective treatment option for patients with brain metastases. Based on the results of brain imaging examinations, doctors will adjust the treatment plan to maximize the control and relief of symptoms of brain metastases.

6. Interactions with other drugs: While taking lorlatinib, patients need to inform their doctor about other drugs they are taking, including prescription drugs, over-the-counter drugs, and supplements. Some drugs may affect the absorption and metabolism of lorlatinib, so doctors need to consider these factors together.

7. Pregnancy and lactation considerations: The effects of lorlatinib on pregnant and lactating women are unknown, so before starting treatment, patients should inform their doctor if they are pregnant or plan to become pregnant. For female patients, it is recommended to use a reliable method of contraception during treatment and for at least one month afterwards to prevent pregnancy.

8. Clinical trials and latest developments: Patients and doctors should stay tuned to the latest clinical trials and research developments to obtain new information and treatment strategies about lorlatinib. Participation in clinical trials may be a way to gain access to the latest treatment options and contribute to scientific research.

Guidelines for the use of lorlatinib need to be adjusted based on individual patient circumstances, genetic testing results, and monitoring during treatment. Patients should maintain close communication with their doctors to jointly develop the most appropriate treatment plan to maximize the effectiveness of the drug while reducing potential adverse reactions and side effects. This individualized approach to treatment helps ensure optimal survival and quality of life for patients.

Lorlatinib has been launched in China and is included in medical insurance. Patients can purchase it domestically, but the price is relatively high, about 10,000 to 20,000 yuan. For specific medical insurance reimbursement prices, please consult the local hospital pharmacy. There are original lorlatinib drugs and cheaper generic drugs abroad. The cheaper ones are the original drug from Turkey, which costs more than 1,000 yuan, and the original drug from Hong Kong, China, which costs about 30,000 yuan. Generic drugs are mainly generic drugs from Laos and Bangladesh. The price is about several thousand yuan, and the ingredients of the original drugs and generic drugs are basically the same.